The first generation of the CRISPR/Cas systems developed by Kantor and colleagues has been proven to be efficient and safe in targeting the regulation of SNCA expression, dysfunction of which has been shown to be the case in Parkinson’s disease (reviewed in (Tagliafierro and Chiba-Falek, 2016)). Here, SNCA is linked to Parkinson disease.